144 results about "Sinus inflammation" patented technology

Methods of treating a central airway obstruction (CAO), benign airway stenosis, asthma, chronic obstructive pulmonary disease (COPD), or an airway tumor in a human subject, methods of treating chronic rhinosinusitis (CRS) or chronic rhinosinusitis with nasal polyps (CRSwNP) in a human subject, methods of treating a eustachian tube disorder in a human subject, and devices and systems for performing the methods. A method of treating a central airway obstruction (CAO), benign airway stenosis, asthma, chronic obstructive pulmonary disease (COPD), or an airway tumor in a human subject includes inserting a drug-coated balloon catheter into a target site in a trachea, mainstem bronchus, bronchus intermedius, lobar bronchus, segmental bronchus, or sub-segmental bronchus, wherein the balloon is coated with a coating layer including the therapeutic agent and one or more additives. The therapeutic agent includes paclitaxel, sirolimus, or a derivative thereof. The method includes inflating the balloon to dilate the airway and deliver a therapeutic agent to the airway wall. The method includes deflating the balloon. The method also includes withdrawing the balloon catheter from the target site.

Methods for treating or preventing chronic rhinosinusitis without nasal polyps (CRSsNP) in a subject are provided. Methods comprising administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody or antigen-binding fragment thereof, are provided.

The invention discloses a chronic sinusitis CT (Computed Tomography) image automatic typing and severity assessment method and a chronic sinusitis CT image automatic typing and severity assessment system based on deep learning. The method comprises the following steps: acquiring paranasal sinus CT image data of a chronic sinusitis patient and an associated clinical tag; carrying out standardization processing on the CT image, wherein the standardization processing comprises gray level normalization, denoising and region-of-interest segmentation; a multi-task deep learning model is constructed, an improved 3D Re < s> Ne < t-50 > architecture is adopted by a typing sub-model to output an immune endotype classification result, and a severity evaluation sub-model segments a lesion area based on a U-Ne < t + + > structure and automatically calculates a severity level; integrating model output to generate individualized treatment suggestions; and superposing a labeling result through the thermodynamic diagram and embedding the labeling result into a hospital PACS system. Accurate typing and evaluation of chronic nasosinusitis are achieved, and diagnosis efficiency and clinical decision support capability are improved.

The invention belongs to the technical field of biological medicine, and relates to application of an OXTR agonist in preparation of a medicine for treating chronic sinusitis (CRS) and respiratory ciliary injury. CRS is treated based on targeted OXTR, and it is found that the OXTR agonist has an excellent treatment effect on promotion of nasal mucosa cilia regeneration and improvement of chronic sinusitis and can promote cilia repair, reduce infiltration of neutrophils and eosinophils and improve the inflammatory environment. In addition, an intranasal treatment dosage form aiming at OXTR is already applied to clinical application of nervous system diseases, the clinical application range of the medicine is expanded, practical feasibility is achieved by improving a better dosage form, and good industrialization prospects are achieved.

Devices, systems, and methods for treating chronic rhinosinutisits (CRS) are described herein. The devices can have a guide member defining at least one lumen therethrough. A drug delivery component is advanced through the lumen to deliver a substance to the sino-nasal cavity of a patient. Once the drug delivery component is positioned at the desired area in the sino-nasal cavity, a user actuates the system to deliver the substance to the target area. Actuation of the system delivers the substance to the middle meatus, osteo-meatal complex, or other areas within the sino-nasal cavity of the patient.

The invention relates to the technical field of traditional Chinese medicine, in particular to a traditional Chinese medicine compound for reducing recurrence of chronic nasosinusitis and a preparation method of the traditional Chinese medicine compound, and the traditional Chinese medicine compound is prepared from, by weight, 14-16 g of radix astragali, 8-10 g of fried radix scutellariae, 8-10 g of radix angelicae, 5-7 g of fructus xanthii, 5-7 g of flos magnoliae, 14-16 g of flos chrysanthemi indici, 11-13 g of fried fructus gardeniae, 5-7 g of radix angelicae sinensis, 5-7 g of flos carthami and 8-10 g of herba menthae. The traditional Chinese medicine composition can significantly improve clinical symptoms of patients with chronic nasosinusitis and reduce the recurrence rate, is good in safety, and does not find abnormal symptoms in clinical use. Meanwhile, the preparation process is simple to operate and suitable for industrial mass production. The raw medicinal materials selected by the traditional Chinese medicine composition are synergistic and complementary in nature and effect, inherit the holism concept of traditional Chinese medicine, emphasize that the traditional Chinese medicine composition emphasizes whole body treatment, plays a role together and inhibits infiltration of inflammatory cells while treating local parts, has small toxic and side effects, fully plays the advantages of treating chronic sinusitis and preventing relapse of the traditional Chinese medicine, relieves the pain of patients, and has a remarkable curative effect on treating chronic sinusitis. The life quality of patients is improved and the recurrence probability is reduced.

The disclosure relates to compounds of the disclosure and pharmaceutically acceptable salts thereof to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of disease(s) such as atopic dermatitis, eosinophilic gastritis, atopic keratoconjunctivitis, allergy, alopecia, Alzheimer's disease, asthma, atherosclerosis, Bechet's disease, bullous pemphigoid, cancer, chronic obstructive pulmonary disease, chronic pruritis, chronic urticaria, Crohn's disease (CD), dermatitis, diabetic kidney disease, eosinophilic esophagitis, fungal keratitis, gout, idiopathic pulmonary fibrosis (IPF), keloids, non-alcoholic steatohepatitis (NASH), primary biliary cirrhosis, prurigo nodularis, psoriasis, psoriatic arthritis, rhinosinusitis, scleroderma, systemic lupus erythematosus (SLE), systemic sclerosis, ulcerative colitis (UC), vitiligo, or hidradenitis suppurativa. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of a dermatological condition or a respiratory condition.

Devices, systems, and methods for treating chronic rhinosinutisits (CRS) are described herein. The devices can have a guide member defining at least one lumen therethrough. A drug delivery component is advanced through the lumen to deliver a substance to the sino-nasal cavity of a patient. Once the drug delivery component is positioned at the desired area in the sino-nasal cavity, a user actuates the system to deliver the substance to the target area. Actuation of the system delivers the substance to the middle meatus, osteo-meatal complex, or other areas within the sino-nasal cavity of the patient.

The invention provides a biomarker composition based on plasma metabonomics and application of the biomarker composition in early diagnosis of nasal extrinsic N / KT cell lymphoma, and relates to the technical field of biomarkers. According to the present invention, for the first time, it is provided that the 2-Methylbutyl beta-D-glucose acid, the 4-(2, 3-dihydro-1, 4-benzodioxin-6-yl) glucose acid and the 4-(octyloxyl) glucose acid can be adopted as the biomarkers for distinguishing the chronic sinusitis patient from the nasal knot external N / KT cell lymphoma patient, and the application of the 2-Methylbutyl beta-D-glucose acid, the 4-(2, 3-dihydro-1, 4-benzodioxin-6-yl) glucose acid, the 4-(2, 3-dihydro-1, 4-benzodioxin-6-yl) glucose acid, the 4-(2, 3-dihydro-1, 4-benzodioxin-6-yl) glucose acid and the 4-( According to the invention, a single-factor prediction model / combined factor prediction model NKTCL early diagnosis model AUCgt is constructed by taking the three biomarkers as characteristics and combining a random forest algorithm; 0.9, sensitivity gt; the specificity is gt; and the kit has relatively high accuracy, sensitivity and specificity for diagnosing the N / KT cell lymphoma outside the nasal knots, and is high in disease diagnosis and prediction capability. According to the method, stepped improvement of diagnosis efficiency is directly achieved through the synergistic effect of the multi-dimensional plasma metabonomics markers and algorithm suitability optimization, and a new normal form with high precision and clinical feasibility is provided for early screening of tumors.

The invention relates to the technical field of traditional Chinese medicine compositions, in particular to a pharmaceutical composition for treating rhinitis and a preparation method and application thereof. The invention provides a pharmaceutical composition for treating rhinitis. The pharmaceutical composition is prepared from the following components in parts by mass: 12-15 parts of astragalus membranaceus, 9-12 parts of codonopsis pilosula, 9-12 parts of houttuynia cordata, 6-9 parts of divaricate saposhnikovia root, 9-12 parts of bighead atractylodes rhizome, 6-9 parts of radix bupleuri, 6-9 parts of ginger processed pinellia, 6-9 parts of fructus forsythiae, 6-9 parts of radix angelicae, 6-9 parts of fried semen armeniacae amarae, 6-9 parts of cocklebur fruit, 6-9 parts of isatis root, 6-9 parts of pogostemon cablin, 3-6 parts of rhodiola rosea, 2-4 parts of schizonepeta, 3-6 parts of dried ginger, 3-5 parts of Chinese date and 3-6 parts of liquorice. The composition provided by the invention is effective for both allergic rhinitis and chronic sinusitis, can relieve acute symptoms and improve chronic inflammation, and overcomes the defect of insufficient pertinence of the existing traditional Chinese medicine compound.

The invention discloses a traditional Chinese medicine preparation for treating chronic rhinitis and chronic nasosinusitis, and relates to the technical field of traditional Chinese medicine preparations. The felwort, the radices stellariae dichotomae, the wine-fried scutellaria baicalensis and the fried cape jasmine are used for treating middle-jiao and upper-jiao, the felwort and the radices stellariae dichotomae are used for clearing damp heat of middle-jiao and lower-jiao, and the fried cape jasmine, the wine-fried scutellaria baicalensis and the lalang grass rhizome are used for removing heat of the upper-jiao; fried cocklebur fruit, angelica dahurica and pogostemon cablin are strong in pungent power, fragrant and capable of opening orifices, and divaricate saposhnikovia root is used for ascending medicine Coix seeds and wax gourd kernels are used for removing dampness and turbidity. The traditional Chinese medicine has the effects of promoting blood circulation and removing blood stasis due to the fact that the peach kernels are independently matched, and the medicines are used together to achieve the effects of ascending lucidity, descending turbid, clearing heat and promoting diuresis.

The invention discloses application of a TGM2 inhibitor in treatment of chronic sinusitis with nasal polyp, asthma and fibrosis complications thereof. Through single cell transcriptome analysis, it is found that the TGM2 is specifically and highly expressed in a macrophage subset (Tgm < 2 + > macrophage) in a CRSwNP sample with asthma, and the TGM2 protein expression level is significantly and positively correlated with the clinical severity of diseases such as CRSwNP and asthma; animal experiments verify that pathological injuries of the nasal cavity and the lung of a Tgm2-knocked-out mouse type 2 inflammation model are relieved, the inflammation of the upper and lower respiratory tracts of the mouse and the fibrosis level of the lung tissue can be remarkably relieved by adopting a small molecule drug ERW1041E for nasal drop administration, and the safety is good; the invention provides a brand-new treatment strategy for patients with diseases related to type 2 inflammation, and has remarkable clinical transformation value and market prospect.

The present invention relates to novel heterocyclic compounds useful in the preparation of medicaments for the treatment of diseases associated with various functions of the histamine 4 receptor.In particular, said drugs are useful for treating inflammatory diseases, allergy, pain, nasal polyps, rhinitis, chronic sinusitis, nasal congestion, nasal itching, asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, atopic dermatitis, psoriasis, eczema, pruritus, itchy skin, urticaria, idiopathic chronic urticaria, scleroderma, conjunctivitis, keratoconjunctivitis, ocular inflammation, dry eye, cardiac dysfunction, arrhythmia, atherosclerosis, multiple sclerosis, inflammatory bowel disease (including colitis, Crohn's disease, ulcerative colitis), inflammatory pain, neuropathic pain, osteoarthritis pain, autoimmune disease, thyroid, immune-mediated (also known as type I) diabetes, lupus, post-surgical adhesions, vestibular disorders and cancer.

Provided herein are methods and uses of antibodies that specifically bind human IL-13 ("anti-IL-13 antibodies") for the treatment of chronic rhinosinusitis with nasal polyps.

The present invention relates to an antisense oligonucleotide targeting an interleukin 4 receptor and the use thereof. The antisense oligonucleotide (ASO) molecule has a length of 16-22 bases and is specifically paired with a specific region of a target gene (interleukin 4 receptor). The ASO is used for treating diseases associated with IL-4Rα, which includes, but is not limited to, asthma (including eosinophilic asthma), atopic dermatitis, eosinophilic esophagitis, sinusitis, nasal polyps, prurigo nodularis, urticaria, chronic obstructive pulmonary disease, bullous pemphigoid, pruritus, and gastritis.

The present application provides a novel combination preparation for use in the treatment of acute, chronic and allergic rhinosinusitis and / or allergic rhinitis which does not cause dry nasal mucosa and is very effective in the treatment of the above diseases. The combination preparation comprises an active ingredient selected from mometasone and / or fluticasone or a pharmaceutically acceptable salt or solvate of any one of the foregoing, in combination with dexpanthenol or a pharmaceutically acceptable salt or solvate thereof, as well as a pharmaceutically acceptable excipient in the form of a nasal spray.

The invention relates to biodegradable intranasal system for the sustained-release of fluticasone propionate in the intranasal cavity, said system comprising a biodegradable polyester matrix that comprises the fluticasone propionate as the active ingredient to be released in the intranasal cavity, wherein the polyester is selected from the list of poly(L,D-lactic acid) (PLA), poly(caprolactone) (PCL), their copolymers such as PLA-PCL, and mixtures thereof; and a method for preparing said system. The invention also relates to a kit comprising the system of the invention and the means of insertion of the system into the nasal cavity. The invention further relates to fluticasone propionate for use for treating chronic rhinitis or chronic sinusitis, wherein the fluticasone propionate is in a form suitable for administration in the nasal cavity by means of the biodegradable intranasal system of the invention.

The present application belongs to the field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition for treating chronic rhinosinusitis in children, a compound preparation of the traditional Chinese medicine composition and application. The present application firstly provides an optimized traditional Chinese medicine formula, which takes Radix Saposhnikoviae, Magnolia flower and Xanthium fruit as monarch drugs, and the weight ratio of the monarch drugs is in the range of 1:6:1 to 1:2:1, which has a significant reducing effect on the expression level of inflammatory factors in chronic rhinosinusitis mice in vivo. Further, the present application provides a compound preparation of the traditional Chinese medicine formula for treating chronic rhinosinusitis in children combined with probiotics, and surprisingly finds that the compound preparation 2 has a more efficient and significant treatment effect than other compound preparations and the control group. The traditional Chinese medicine formula and the probiotics have a synergistic effect when combined in a weight ratio of 10:2. The present application has important significance in providing a preparation with the characteristics of no drug resistance, no side effect and fast effect for children with chronic rhinosinusitis.

The invention relates to allergy, and to the treatment, amelioration or prevention of symptoms of allergy, such as rhinitis, allergic rhinitis and rhinosinusitis. The invention is especially concerned with the use of inactivated or killed bacterial spores in treating, preventing or ameliorating allergy or allergic reactions, and in particular, symptoms of allergy, including rhinitis, rhinosinusitis and allergic rhinitis. The invention extends to dead or inactivated spores, compositions (both pharmaceutical and non-pharmaceutical) comprising such spores and methods of making the compositions.

The present invention discloses a novel stable, single phase aqueous suspension for nasal administration to treat bacterial sinusitis. The composition takes azithromycin dihydrate as an active ingredient, and adopts a suspending agent system to prevent phase separation during storage. Embodiments include a formulation comprising a sorbitan monolaurate, or a combination of chitosan and a sorbitan monolaurate, to maintain the stability of the suspension. The present invention has a variety of advantages, including local delivery of azithromycin to an infected site, which can reduce systemic exposure and associated side effects compared to oral formulations.

The disclosure relates to compounds of the disclosure and pharmaceutically acceptable salts thereof to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of disease(s) such as atopic dermatitis, eosinophilic gastritis, atopic keratoconjunctivitis, allergy, alopecia, Alzheimer's disease, asthma, atherosclerosis, Bechet's disease, bullous pemphigoid, cancer, chronic obstructive pulmonary disease, chronic pruritis, chronic urticaria, Crohn's disease (CD), dermatitis, diabetic kidney disease, eosinophilic esophagitis, fungal keratitis, gout, idiopathic pulmonary fibrosis (IPF), keloids, non-alcoholic steatohepatitis (NASH), primary biliary cirrhosis, prurigo nodularis, psoriasis, psoriatic arthritis, rhinosinusitis, scleroderma, systemic lupus erythematosus (SLE), systemic sclerosis, ulcerative colitis (UC), vitiligo, or hidradenitis suppurativa. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of a dermatological condition or a respiratory condition.

The invention belongs to the technical field of biological medicines, and relates to an efficient affinity anti-human IL-33 monoclonal antibody and a preparation method thereof. The monoclonal antibody provided by the invention has good specificity and affinity, accurately targets a key cell factor IL-33, and effectively blocks a binding path between the key cell factor IL-33 and a receptor ST2. As a core factor mediating various inflammatory diseases, such as asthma, allergic dermatitis, chronic sinusitis, chronic obstructive pulmonary disease (COPD) and the like, IL-33 is crucial in intervention of a regulation mechanism for disease treatment. The monoclonal antibody disclosed by the invention is novel in sequence, and provides a new thought for preparation of the medicine by inhibiting IL-33 mediated inflammatory reaction.

The invention belongs to the technical field of medicine, and discloses a medicinal sponge sheet for inhibiting growth of nasal polyp, the medicinal sponge sheet is composed of a medical grade absorptive gelatin sponge base material, triamcinolone acetonide and hydroxypropyl methyl cellulose, the medicinal sponge sheet adopts the medical gelatin base material with the porosity of 95% and the water absorption expansion rate of less than or equal to 30%, the size is 60mm * 20mm * 5mm, each sheet loads 60mg of triamcinolone acetonide, and the hydroxypropyl methyl cellulose is added into the medicinal sponge sheet. And 10% of hydroxypropyl methyl cellulose with the molecular weight of 35000 Da and the viscosity of 700 mPa.s is supplemented to construct a slow release system. Efficient and safe treatment of chronic nasosinusitis with nasal polyp is achieved through multi-dimensional innovative design, the three-dimensional interpenetrating pore structure of the medical gelatin base material provides an ideal carrier for drug release, 60%-70% of triamcinolone acetonide is continuously released within 7 days through the gradient slow release technology, a local high-concentration microenvironment is constructed, and the effect of treating chronic nasosinusitis with nasal polyp is achieved. The device directly acts on the polyp root to block an inflammation cascade reaction; in the formula, hydroxypropyl methyl cellulose is used as a core slow-release carrier.

The invention provides a budesonide temperature-sensitive gel preparation as well as a preparation method and application thereof, and the budesonide temperature-sensitive gel preparation is mainly prepared from the following components: budesonide, poloxamer 407, poloxamer 188, propylene glycol, hydroxypropyl methyl cellulose, sodium benzoate and pure water. After the budesonide temperature-sensitive gel drug delivery system based on poloxamer 407, poloxamer 188 and hydroxypropyl methylcellulose is applied to a cavity, semi-solid gel can be quickly formed, and strong retention and slow release effects are shown, so that the bioavailability is increased, the formed semi-solid gel can be retained at a drug delivery part and cannot be lost, and the budesonide temperature-sensitive gel drug delivery system is suitable for clinical application. In addition, budesonide can be gradually released, and a remarkable curative effect is shown in short-term clinical application of recurrent chronic sinusitis with nasal polyp.

Methods for treating or preventing chronic rhinosinusitis without nasal polyps (CRSsNP) in a subject are provided. Methods comprising administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody or antigen-binding fragment thereof, are provided.

The present invention relates to a composition comprising the combination of extracts from Centella asiatica or other members of the family Apiaceae, extract from the family Zingiberaceae, extract from the family Valerianaceae, extract from the family Capsicum, xylitol, sodium hyaluronate, glycerine, vitamins and minerals for treating and / or alleviating snoring, chronic sinusitis, cold, and / or obstructive sleep apnea in humans and animals.

The application discloses application of a CGRP receptor small molecule antagonist in preparation of a medicine for treating chronic rhinosinusitis with nasal polyps. The medicine preparation is composed of an effective amount of the CGRP receptor small molecule antagonist and pharmaceutically acceptable adjuvants, and the dosage form is a nasal spray / drop / irrigation agent, and the administration route is simple and easy to operate, and is convenient for patients to use. The application can significantly reduce eosinophilic inflammation by inhibiting CGRP-mediated mast cell activation, and has a clear treatment advantage for eosinophilic nasal polyps. Compared with a biological preparation targeting type 2 cytokines, a small molecule compound is safer and simpler to obtain, can significantly reduce the treatment cost of patients, and provides a new efficient and economical choice for nasal polyp treatment.

The present disclosure relates generally to methods of treating chronic sinusitis with or without nasal polyp using antibodies specific for thymic stromal lymphopoietin (TSLP).

Provided herein are pharmaceutical compositions, therapeutic combinations, devices and methods for treating, ameliorating, reversing, causing the remission of, and / or preventing (acting as a prophylaxis, or preventing the initiation of) an inflammatory bowel disorder (IBD) or inflammatory bowel disease (IBD), Ulcerative Colitis; Crohn's disease; J-pouch; fistulising Crohn's disease; a Colitis which can be microscopic, lymphocytic or collagenous; an eosinophilic colitis; indeterminate colitis; idiopathic colitis; diverticulosis and diverticulitis; relapsing diverticulitis; constipation associated inflammatory bowel disease and / or small intestinal bacterial overgrowth; Irritable Bowel Syndrome (IBS) with or without diarrhoea, constipation or pain predominant IBS; periodontitis; rheumatoid arthritis; respiratory infections, appendicitis, vascular disorders such as thrombophlebitis; bacteremia; osteomyelitis; septic shock; Alzheimer's disease; Lemierre syndrome (postanginal sepsis); colonic polyps or adenomas (optionally hyperplastic, adenomatous or serrated adenomas) or preventing the growth of colonic polyps or adenomas, bowl cancer, or metastases (optionally preventing the initiation or promotion of bowl cancer or metastasis); pharyngitis; otitis; sinusitis; and any disease, symptom or condition caused or exacerbated by a Fusobacteria (optionally, a F. nucleatum or F. varium) infection. In alternative embodiments, pharmaceutical compositions comprise rifaximin alone or in combination with other antibiotics or drugs.

The present application relates to treatment of nasal cavity inflammation and mucus hypersecretion. One aspect of the present invention is a method of treatment of rhinitis and rhinosinusitis, wherein the treatment reduces nasal stuffiness, nasal congestion, and phlegm secretion. Reduction of phlegm secretion from the nasal cavity into the pharynx can also reduce cough frequency from infectious and allergic rhinitis. In the preferred embodiment, FEMA 4557, is an example of a molecule, topically applied to the nasal mucosa, that can be used to treat rhinitis. FEMA 4557 is a potent non-irritating suppressor of acute inflammation in the nasal cavity and sinuses, a property not previously described for other topical cooling agents. Thus, FEMA 4557 and related analogs may have therapeutic utility for treating nasal inflammation and mucus hypersecretion.